https://www.curevac.com/curevacs-coronavirus-impfstoffkandidat-zeigt-dank-optimierter-mrna-plattform-positive-praeklinische-ergebnisse-bei-niedriger-dosierung/ 2020-06-30T19:03:48+00:00 https://www.curevac.com/curevac-ceo-daniel-menichella-beraet-mit-us-praesident-donald-trump-und-mitgliedern-der-corona-task-force-entwicklungsmoeglichkeiten-eines-coronavirus-impfstoffes/ 2020-06-30T19:04:02+00:00 https://www.curevac.com/studie-in-renommierter-fachzeitschrift-vaccine-entschluesselt-wirkweise-innovativer-mrna-impfstoffe/ 2020-07-20T02:31:31+00:00 https://www.curevac.com/curevac-ernennt-pierre-kemula-zum-neuen-finanzvorstand/ 2020-07-20T02:40:46+00:00 https://www.curevac.com/curevac-erhaelt-umfassendes-patent-fuer-wegweisende-rnantibody-technologie/ 2020-07-20T02:50:28+00:00 https://www.curevac.com/data-published-in-nature-biotechnology-show-messenger-mrna-prophylactic-vaccines-based-on-curevacs-rnactive-technology-demonstrate-immunogenicity-and-protection-against-influenza-viru/ 2020-07-20T10:15:43+00:00 https://www.curevac.com/medizinische-wirkstoffe-auf-basis-von-messenger-rna-erhalten-eigenes-namenssuffix-durch-who/ 2020-07-20T10:37:41+00:00 https://www.curevac.com/curevacs-ceo-ingmar-hoerr-is-keynote-speaker-at-the-cancer-vaccines-and-gene-therapy-meeting-2013-in-philadelphia/ 2020-07-20T10:50:13+00:00 https://www.curevac.com/en/curevacs-ceo-ingmar-hoerr-is-keynote-speaker-at-the-cancer-vaccines-and-gene-therapy-meeting-2013-in-philadelphia/ 2020-07-20T10:51:14+00:00 https://www.curevac.com/curevac-cancer-research-institute-und-ludwig-cancer-research-schmieden-allianz-fuer-klinische-pruefung-von-krebs-immuntherapien/ 2020-07-20T11:08:00+00:00 https://www.curevac.com/curevac-schliesst-patientenrekrutierung-fuer-klinische-phase-iib-studie-seiner-mrna-basierten-prostatakrebstherapie-ab/ 2020-07-20T11:16:53+00:00 https://www.curevac.com/bill-melinda-gates-stiftung-investiert-in-curevac-zur-entwicklung-innovativer-impfstoffe/ 2020-07-20T11:31:52+00:00 https://www.curevac.com/curevac-veroeffentlicht-daten-aus-seiner-klinischen-phase-i-iia-studie-zur-mrna-basierten-krebsimmuntherapie-bei-prosta-takarzinom-im-journal-for-immunotherapy-of-cancer/ 2020-07-20T12:00:13+00:00 https://www.curevac.com/curevac-to-present-at-biocenturys-22nd-annual-newsmakers-in-the-biotech-industry-conference/ 2020-07-20T12:12:45+00:00 https://www.curevac.com/curevac-gruendet-us-amerikanische-tochtergesellschaft-in-cambridge/ 2020-07-20T12:20:51+00:00 https://www.curevac.com/curevac-erzielt-100-millionen-euro-in-neuer-finanzierungsrunde/ 2020-07-20T12:29:56+00:00 https://www.curevac.com/curevac-beginnt-klinische-phase-2b-studie-seines-mrna-basierten-krebsimpfstoffs-bei-patienten-mit-kastrationsresistentem-prostatakrebs/ 2020-07-20T12:45:59+00:00 https://www.curevac.com/curevac-gibt-zusammenarbeit-mit-janssen-an-der-entwicklung-eines-mrna-basierten-grippeimpfstoffs-bekannt/ 2020-07-20T20:26:36+00:00 https://www.curevac.com/en/curevac-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference/ 2020-07-20T23:50:00+00:00 https://www.curevac.com/curevac-verstaerkt-seinen-aufsichtsrat-um-angesehene-pharma-experten/ 2020-07-21T00:11:19+00:00 https://www.curevac.com/en/iavi-and-curevac-partner-to-accelerate-development-and-testing-of-aids-vaccine-candidates/ 2020-07-21T01:17:30+00:00 https://www.curevac.com/en/data-published-in-nature-biotechnology-show-messenger-mrna-prophylactic-vaccines-based-on-curevacs-rnactive-technology-demonstrate-immunogenicity-and-protection-against-influenza-viru/ 2020-07-21T01:27:41+00:00 https://www.curevac.com/en/curevac-secures-e80-million-in-series-d-financing/ 2020-07-21T01:28:22+00:00 https://www.curevac.com/curevac-erhaelt-80-millionen-euro-in-weiterer-finanzierungsrunde/ 2020-07-21T01:28:45+00:00 https://www.curevac.com/curevac-to-present-at-the-j-p-morgan-35th-annual-healthcare-conference-2017/ 2020-07-21T01:33:23+00:00 https://www.curevac.com/curevac-erhaelt-weitere-265-mio-euro-von-zwei-neuen-investoren/ 2020-07-21T01:38:31+00:00 https://www.curevac.com/en/curevac-announces-meran-has-been-approved-by-the-world-health-organization-as-suffix-for-mrna-drug-substances/ 2020-07-21T01:44:43+00:00 https://www.curevac.com/curevac-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference/ 2020-07-21T01:45:28+00:00 https://www.curevac.com/iavi-und-curevac-gehen-partnerschaft-zur-beschleunigten-entwicklung-und-pruefung-von-impfstoffen-gegen-aids-ein/ 2020-07-21T01:46:19+00:00 https://www.curevac.com/en/curevac-establishes-u-s-operations-in-cambridge-ma/ 2020-07-21T01:46:53+00:00 https://www.curevac.com/en/curevac-to-present-at-biocenturys-22nd-annual-newsmakers-in-the-biotech-industry-conference/ 2020-07-21T01:47:27+00:00 https://www.curevac.com/en/collaboration-to-develop-mrna-vaccines-expands/ 2020-07-21T01:49:51+00:00 https://www.curevac.com/ausbau-der-kooperation-zur-entwicklung-mrna-basierter-impfstoffe/ 2020-07-21T01:50:53+00:00 https://www.curevac.com/en/curevac-announces-study-publication-in-molecular-therapy-demonstrating-wide-ranging-benefits-of-sequence-optimized-unmodified-mrnas/ 2020-07-21T01:51:20+00:00 https://www.curevac.com/curevac-announces-study-publication-in-molecular-therapy-demonstrating-wide-ranging-benefits-of-sequence-optimized-unmodified-mrnas/ 2020-07-21T01:51:56+00:00 https://www.curevac.com/en/curevac-announces-phase-i-iia-clinical-study-data-of-its-mrna-cancer-immunotherapy-in-prostate-cancer-published-in-the-journal-for-immunotherapy-of-cancer/ 2020-07-21T01:52:28+00:00 https://www.curevac.com/en/the-bill-melinda-gates-foundation-and-curevac-collaborate-to-accelerate-the-development-of-transformative-vaccine-technology/ 2020-07-21T01:53:19+00:00 https://www.curevac.com/en/curevac-completes-patient-recruitment-for-phase-iib-clinical-trial-of-mrna-based-prostate-cancer-treatment/ 2020-07-21T01:54:04+00:00 https://www.curevac.com/en/1st-international-mrna-health-conference-in-tubingen-heralds-a-new-era-in-modern-medicine/ 2020-07-21T01:54:52+00:00 https://www.curevac.com/1-international-mrna-health-conference-in-tuebingen-kuendigt-eine-neue-aera-in-der-modernen-medizin-an/ 2020-07-21T01:55:31+00:00 https://www.curevac.com/en/curevac-collaborates-with-the-cancer-research-institute-and-ludwig-cancer-research-to-enable-clinical-testing-of-novel-immunotherapy-treatment-options-for-cancer/ 2020-07-21T01:56:06+00:00 https://www.curevac.com/en/curevac-to-collaborate-with-janssen-on-development-of-mrna-based-influenza-vaccine/ 2020-07-21T01:57:08+00:00 https://www.curevac.com/en/curevac-initiates-phase-2b-clinical-trial-of-its-mrna-based-cancer-vaccine-in-patients-with-castration-resistant-prostate-cancer/ 2020-07-21T01:59:20+00:00 https://www.curevac.com/en/curevac-raises-110-million-in-a-private-placement/ 2020-07-21T02:10:12+00:00 https://www.curevac.com/covid-19-conference-call-zur-aktuellen-entwicklung/ 2020-07-22T13:23:20+00:00 https://www.curevac.com/curevac-mit-neuigkeiten-zum-vorstand/ 2020-07-22T13:34:44+00:00 https://www.curevac.com/curevac-fokussiert-sich-auf-die-entwicklung-eines-mrna-basierten-coronavirus-impfstoffs-zum-schutz-der-menschen-weltweit/ 2020-07-22T13:43:24+00:00 https://www.curevac.com/wechsel-im-vorstand-von-curevac-unternehmensgruender-ingmar-hoerr-folgt-auf-ceo-daniel-menichella/ 2020-07-22T13:46:48+00:00 https://www.curevac.com/curevac-ernennt-dr-alan-kimura-zum-leiter-der-neu-geschaffenen-abteilung-seltene-erkrankungen/ 2020-07-22T13:54:54+00:00 https://www.curevac.com/curevac-berichtet-positive-ergebnisse-aus-niedrig-dosierter-1-%c2%b5g-phase-1-studie-mit-tollwut-impfstoff/ 2020-07-22T14:49:51+00:00 https://www.curevac.com/genmab-und-curevac-gehen-strategische-partnerschaft-zur-entwicklung-von-mrna-basierten-antikoerper-therapeutika-ein/ 2020-07-22T19:20:00+00:00 https://www.curevac.com/curevac-erhaelt-herstellungserlaubnis-fuer-dritte-gmp-produktion/ 2020-07-22T19:35:53+00:00 https://www.curevac.com/en/curevac-to-participate-in-two-panels-at-the-roth-rna-revolution-conference/ 2020-07-22T21:10:04+00:00 https://www.curevac.com/curevac-nimmt-an-zwei-panels-der-roth-rna-revolution-conference-teil/ 2020-07-22T21:10:45+00:00 https://www.curevac.com/die-europaeische-kommission-beruft-ingmar-hoerr-mitgruender-und-aufsichtsratsvorsitzender-von-curevac-zum-beirat-des-europaeischen-innovationsrats/ 2020-07-22T21:12:49+00:00 https://www.curevac.com/en/european-commission-appoints-curevac-co-founder-supervisory-board-chairman-ingmar-hoerr-to-the-european-innovation-council-advisory-board/ 2020-07-22T21:15:24+00:00 https://www.curevac.com/en/curevac-receives-grants-for-three-patents-regarding-intratumoral-application-of-rna/ 2020-07-22T21:32:46+00:00 https://www.curevac.com/curevac-werden-drei-patente-zur-intratumoralen-applikation-von-rna-erteilt/ 2020-07-22T21:33:48+00:00 https://www.curevac.com/en/curevac-enters-into-an-exclusive-sponsored-research-agreement-for-discovery-research-in-mrna-based-eye-therapy-candidates-with-the-schepens-eye-research-institute-harvard-medical-school-and-the-massa/ 2020-07-22T21:37:49+00:00 https://www.curevac.com/exklusive-forschungskooperation-zwischen-curevac-und-dem-schepens-eye-research-institute-der-harvard-medical-school/ 2020-07-22T21:38:18+00:00 https://www.curevac.com/en/curevac-granted-patent-claiming-the-combination-of-mrna-vaccines-with-anti-pd-l1-antibodies/ 2020-07-22T21:53:00+00:00 https://www.curevac.com/curevac-erhaelt-patent-fuer-die-kombination-mrna-basierter-impfstoffe-und-anti-pd-l1-antikoerper/ 2020-07-22T21:53:59+00:00 https://www.curevac.com/curevac-nimmt-an-bevorstehenden-investorenkonferenzen-teil/ 2020-07-22T21:55:03+00:00 https://www.curevac.com/en/curevac-to-participate-in-upcoming-investor-conferences/ 2020-07-22T21:56:56+00:00 https://www.curevac.com/curevac-praesentiert-auf-der-8th-leerink-partners-global-healthcare-conference/ 2020-07-22T22:35:02+00:00 https://www.curevac.com/en/curevac-to-present-at-the-8th-annual-leerink-partners-global-healthcare-conference/ 2020-07-22T22:36:21+00:00 https://www.curevac.com/curevac-ernennt-dr-stefan-mueller-zum-vice-president-preclinical/ 2020-07-22T22:40:58+00:00 https://www.curevac.com/en/curevac-appoints-stefan-mueller-ph-d-as-vice-president-preclinical/ 2020-07-22T22:44:28+00:00 https://www.curevac.com/en/curevac-appoints-dimitris-voliotis-m-d-dr-med-as-chief-development-officer/ 2020-07-22T22:56:35+00:00 https://www.curevac.com/curevac-ernennt-dr-med-dimitris-voliotis-md-zum-chief-development-officer/ 2020-07-22T22:56:52+00:00 https://www.curevac.com/curevac-praesentiert-auf-der-19th-annual-piper-jaffray-healthcare-conference/ 2020-07-22T23:10:36+00:00 https://www.curevac.com/en/curevac-to-present-at-the-19th-annual-piper-jaffray-healthcare-conference/ 2020-07-22T23:12:15+00:00 https://www.curevac.com/die-universitaet-tuebingen-verleiht-die-ehrensenatorenwuerde-an-dr-ingmar-hoerr-mitgruender-und-aufsichtsratsvorsitzenden-der-curevac-ag/ 2020-07-23T03:58:10+00:00 https://www.curevac.com/en/university-of-tubingen-names-curevac-co-founder-supervisory-board-chairman-ingmar-hoerr-honorary-senator/ 2020-07-23T03:59:27+00:00 https://www.curevac.com/boehringer-ingelheim-und-curevac-entwickeln-gemeinsam-immuntherapie-gegen-lungenkrebs/ 2020-07-23T04:11:07+00:00 https://www.curevac.com/en/boehringer-ingelheim-and-curevac-announce-collaboration-to-develop-next-generation-lung-cancer-immunotherapy/ 2020-07-23T04:20:21+00:00 https://www.curevac.com/curevac-announces-appointment-of-matthew-l-s-beck-as-vice-president-of-investor-relations/ 2020-07-23T04:24:37+00:00 https://www.curevac.com/curevac-presents-clinical-results-of-a-phase-i-iia-trial-in-non-small-cell-lung-cancer-nsclc/ 2020-07-23T04:27:24+00:00 https://www.curevac.com/en/curevac-presents-clinical-results-of-a-phase-i-iia-trial-in-non-small-cell-lung-cancer-nsclc/ 2020-07-23T04:28:37+00:00 https://www.curevac.com/veraenderung-an-der-spitze-von-curevac/ 2020-07-23T04:30:28+00:00 https://www.curevac.com/en/curevac-announces-new-management-structure/ 2020-07-23T04:32:12+00:00 https://www.curevac.com/curevac-receives-u-s-patent-covering-entire-process-for-pharmaceutical-manufacturing-of-rna/ 2020-07-23T04:34:01+00:00 https://www.curevac.com/en/curevac-receives-u-s-patent-covering-entire-process-for-pharmaceutical-manufacturing-of-rna/ 2020-07-23T04:34:35+00:00 https://www.curevac.com/curevac-entwickelt-innovative-mrna-impfstoffe-gegen-influenza-und-malaria/ 2020-07-23T04:36:25+00:00 https://www.curevac.com/en/curevac-to-pursue-innovative-mrna-vaccines-against-flu-and-malaria/ 2020-07-23T04:37:46+00:00 https://www.curevac.com/curevac-baut-patentportfolio-seiner-mrna-basierten-impfstoffe-und-therapeutika-aus/ 2020-07-23T04:38:47+00:00 https://www.curevac.com/en/curevac-expands-intellectual-property-position-that-significantly-improves-protein-expression-for-its-mrna-based-vaccines-and-therapeutics/ 2020-07-23T04:41:43+00:00 https://www.curevac.com/curevac-stellt-auf-der-j-p-morgan-healthcare-conference-in-san-francisco-unternehmerische-meilensteine-und-ausblick-auf-2018-vor/ 2020-07-23T04:42:53+00:00 https://www.curevac.com/en/curevac-highlights-key-2018-corporate-milestones-and-outlook/ 2020-07-23T04:46:27+00:00 https://www.curevac.com/5th-international-mrna-health-conference-highlights-rapid-clinical-progress-and-cross-industry-collaboration/ 2020-07-27T22:43:03+00:00 https://www.curevac.com/en/5th-international-mrna-health-conference-highlights-rapid-clinical-progress-and-cross-industry-collaboration/ 2020-07-27T22:44:23+00:00 https://www.curevac.com/grundstein-fuer-hochmodernes-labor-und-forschungsgebaeude/ 2020-07-27T22:49:50+00:00 https://www.curevac.com/en/curevac-announces-groundbreaking-of-industrial-scale-gmp-production-facility-for-rna-therapeutics/ 2020-07-27T22:58:36+00:00 https://www.curevac.com/curevac-startet-klinische-studie-mit-rna-basiertem-krebswirkstoff-zur-intratumoralen-anwendung/ 2020-07-27T22:59:36+00:00 https://www.curevac.com/en/curevac-initiates-phase-i-clinical-trial-of-rnadjuvant-candidate-as-intratumoral-therapy-for-solid-tumors/ 2020-07-27T23:01:08+00:00 https://www.curevac.com/publikation-in-npj-vaccines-beschreibt-vorteile-mrna-basierter-impfstoffe-gegenueber-zugelassenen-impfstoffe/ 2020-07-27T23:01:54+00:00 https://www.curevac.com/en/publication-in-npj-vaccines-demonstrates-curevacs-rnactive-vaccine-is-superior-to-licensed-vaccines/ 2020-07-27T23:03:38+00:00 https://www.curevac.com/lilly-und-curevac-entwickeln-gemeinsam-mrna-krebsimmuntherapien/ 2020-07-27T23:05:42+00:00 https://www.curevac.com/en/lilly-and-curevac-announce-global-collaboration-to-develop-mrna-cancer-vaccines/ 2020-07-27T23:07:00+00:00 https://www.curevac.com/curevac-veroeffentlicht-wegweisende-studie-zur-antikoerpertherapie-auf-basis-von-messenger-rna/ 2020-07-27T23:07:47+00:00 https://www.curevac.com/5th-international-mrna-health-conference-to-showcase-tremendous-advances-in-the-development-of-mrna-drugs/ 2020-07-27T23:13:15+00:00 https://www.curevac.com/en/5th-international-mrna-health-conference-to-showcase-tremendous-advances-in-the-development-of-mrna-drugs/ 2020-07-27T23:13:46+00:00 https://www.curevac.com/en/curevac-to-receive-patent-claiming-the-combination-of-mrna-vaccines-with-anti-pd-1-antibodies/ 2020-07-27T23:22:44+00:00 https://www.curevac.com/curevac-erhaelt-patent-fuer-die-kombination-von-mrna-impfstoffen-und-anti-pd-1-antikoerpern/ 2020-07-27T23:24:18+00:00 https://www.curevac.com/curevac-ag-baut-mrna-wirkstoffproduktion-am-standort-tuebingen-aus-versorgung-klinischer-studien-und-spaetere-kommerzielle-verfuegbarkeit-der-curevac-produkte-gesichert/ 2020-07-27T23:46:35+00:00 https://www.curevac.com/en/curevac-expands-gmp-production-capacities-for-rna-products/ 2020-07-27T23:48:00+00:00 https://www.curevac.com/curevac-ag-baut-patentschutz-fuer-innovative-mrna-impfstoffe-weltweit-aus/ 2020-07-27T23:49:25+00:00 https://www.curevac.com/en/curevac-extends-global-intellectual-property-estate-for-prophylactic-mrna-vaccines/ 2020-07-27T23:51:44+00:00 https://www.curevac.com/curevac-to-present-at-upcoming-international-investor-conferences/ 2020-07-27T23:55:11+00:00 https://www.curevac.com/en/curevac-to-present-at-upcoming-international-investor-conferences/ 2020-07-27T23:55:49+00:00 https://www.curevac.com/curevac-appoints-daniel-menichella-as-ceo-of-curevac-inc-the-companys-us-subsidiary/ 2020-07-27T23:58:23+00:00 https://www.curevac.com/en/curevac-appoints-daniel-menichella-as-ceo-of-curevac-inc-the-companys-us-subsidiary/ 2020-07-27T23:59:20+00:00 https://www.curevac.com/europaeische-kommission-beruft-ingmar-hoerr-in-high-level-group-der-innovatoren/ 2020-07-28T00:01:16+00:00 https://www.curevac.com/en/curevacs-ceo-ingmar-hoerr-appointed-by-european-commission-to-high-level-group/ 2020-07-28T00:02:26+00:00 https://www.curevac.com/en/curevacs-optimized-mrna-platform-provides-positive-pre-clinical-results-at-low-dose-for-coronavirus-vaccine-candidate/ 2020-07-28T20:47:44+00:00 https://www.curevac.com/en/curevac-strengthens-supervisory-board-to-support-global-growth-opportunities-and-mrna-product-expansion/ 2020-07-29T03:39:17+00:00 https://www.curevac.com/curevac-erweitert-seinen-wissenschaftlichen-beirat-um-re-nommierte-experten/ 2020-07-29T13:55:12+00:00 https://www.curevac.com/en/curevac-appoints-leading-experts-to-its-scientific-advisory-board/ 2020-07-29T13:55:43+00:00 https://www.curevac.com/en/study-in-peer-reviewed-journal-vaccine-demonstrates-decoding-mode-of-action-of-mrna-vaccines/ 2020-07-29T14:08:08+00:00 https://www.curevac.com/en/curevac-appoints-pierre-kemula-as-chief-financial-officer/ 2020-07-29T14:17:12+00:00 https://www.curevac.com/en/curevac-receives-broad-patent-for-rnantibody-technology/ 2020-07-29T14:18:33+00:00 https://www.curevac.com/en/curevac-secures-an-additional-29-5-million-from-two-new-investors/ 2020-07-29T14:20:27+00:00 https://www.curevac.com/study-with-curevacs-rnadjuvant-technology-published-in-cancer-immunology-immunotherapy-demonstrates-equal-responsiveness-of-blood-cells-from-both-hepatocellular-carcinoma-hcc-patien/ 2020-07-29T14:23:36+00:00 https://www.curevac.com/en/study-with-curevacs-rnadjuvant-technology-published-in-cancer-immunology-immunotherapy-demonstrates-equal-responsiveness-of-blood-cells-from-both-hepatocellular-carcinoma-hcc-patien/ 2020-07-29T14:25:12+00:00 https://www.curevac.com/en/curevac-to-present-at-the-j-p-morgan-35th-annual-healthcare-conference-2017/ 2020-07-29T14:27:21+00:00 https://www.curevac.com/en/curevac-granted-manufacturing-authorization-for-its-third-gmp-production-suite/ 2020-07-29T14:34:01+00:00 https://www.curevac.com/en/genmab-and-curevac-enter-strategic-partnership-to-develop-mrna-based-antibody-therapeutics/ 2020-07-29T14:36:10+00:00 https://www.curevac.com/en/curevac-announces-positive-results-in-low-dose-1-%c2%b5g-rabies-vaccine-clinical-phase-1-study/ 2020-07-29T14:38:34+00:00 https://www.curevac.com/en/curevac-appoints-alan-kimura-md-phd-as-head-of-the-newly-created-department-rare-diseases/ 2020-07-29T14:43:40+00:00 https://www.curevac.com/en/curevac-ceo-daniel-menichella-discusses-coronavirus-vaccine-development-with-u-s-president-donald-trump-and-members-of-coronavirus-task-force/ 2020-07-29T14:46:00+00:00 https://www.curevac.com/en/company-founder-ingmar-hoerr-succeeds-daniel-menichella-as-ceo-of-curevac-ag/ 2020-07-29T14:48:06+00:00 https://www.curevac.com/en/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide/ 2020-07-29T14:49:58+00:00 https://www.curevac.com/en/curevac-announces-leadership-update/ 2020-07-29T15:00:28+00:00 https://www.curevac.com/en/covid-19-conference-call-on-current-developments/ 2020-07-29T15:03:23+00:00 https://www.curevac.com/en/jean-stephenne-elected-as-new-chairman-of-the-supervisory-board-of-curevac/ 2020-07-29T15:06:10+00:00 https://www.curevac.com/en/publication-in-embo-molecular-medicine-demonstrates-curevacs-proprietary-mrna-technology-enables-antibody-mediated-therapies-against-infectious-agents-toxins-and-tumors/ 2020-08-14T03:18:47+00:00 https://www.curevac.com/curevac-erhaelt-von-deutschen-und-belgischen-zulassungsbehoerden-gruenes-licht-zum-start-der-klinischen-phase-1-mit-seinem-sars-cov-2-impfstoffkandidaten/ 2020-08-14T15:00:46+00:00 https://www.curevac.com/en/curevac-receives-regulatory-approval-from-german-and-belgian-authorities-to-initiate-phase-1-clinical-trial-of-its-sars-cov-2-vaccine-candidate/ 2020-08-14T15:05:40+00:00 https://www.curevac.com/curevac-und-europaeische-kommission-in-fortgeschrittenen-gespraechen-ueber-die-bereitstellung-von-bis-zu-405-millionen-dosen-eines-potenziellen-mrna-basierten-covid-19-impfstoffs/ 2020-08-20T10:40:51+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/en/curevac-and-european-commission-in-advanced-discussions-to-supply-up-to-405-million-doses-of-potential-mrna-based-covid-19-vaccine/ 2020-08-20T10:41:37+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/curevac-kuendigt-den-abschluss-des-ersten-oeffentlichen-zeichnungsangebots-an/ 2020-08-24T04:44:05+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/en/curevac-announces-closing-of-initial-public-offering/ 2020-08-24T04:45:23+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/en/curevac-expected-to-receive-up-to-252-million-euros-from-the-german-federal-ministry-of-research-for-further-covid-19-vaccine-development-and-production-capacity-expansion/ 2020-09-07T10:37:02+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/curevac-erhaelt-vom-bundesforschungsministerium-voraussichtlich-bis-zu-252-millionen-euro-fuer-weitere-covid-19-impfstoffentwicklung-und-ausbau-der-produktionskapazitaeten/ 2020-09-07T10:39:52+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/curevac-startet-mit-covid-19-impfstoffkandidat-klinische-phase-2a-studie/ 2020-09-29T20:13:29+00:00 https://www.curevac.com/en/curevac-initiates-phase-2a-clinical-trial-of-covid-19-vaccine-candidate/ 2020-09-29T20:13:53+00:00 https://www.curevac.com/en/curevac-reports-positive-preclinical-data-for-its-covid-19-vaccine-candidate-cvncov/ 2020-10-23T11:19:18+00:00 https://www.curevac.com/curevac-meldet-positive-praeklinische-daten-fuer-seinen-covid-19-impfstoffkandidaten-cvncov/ 2020-10-23T11:22:14+00:00 https://www.curevac.com/en/curevac-reports-positive-interim-phase-1-data-for-its-covid-19-vaccine-candidate-cvncov/ 2020-11-02T12:00:40+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/curevac-berichtet-positive-phase-1-interimsdaten-fuer-seinen-covid-19-impfstoffkandidaten-cvncov/ 2020-11-02T12:01:18+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/jean-stephenne-elected-as-new-chairman-of-the-supervisory-board-of-curevac/ 2020-11-03T15:30:57+00:00 https://www.curevac.com/curevac-veroeffentlicht-detaillierte-interimsdaten-der-phase-1-studie-seines-covid-19-impfstoffkandidaten-cvncov/ 2020-11-10T12:00:16+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-publishes-detailed-interim-phase-1-data-of-its-covid-19-vaccine-candidate-cvncov/ 2020-11-10T12:00:38+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevacs-covid-19-vaccine-candidate-cvncov-suitable-for-standard-fridge-temperature-logistics/ 2020-11-12T12:00:57+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevacs-covid-19-impfstoffkandidat-cvncov-fuer-logistik-bei-kuehlschranktemperatur-geeignet/ 2020-11-12T12:00:57+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/europaeische-kommission-kuendigt-an-dass-sie-morgen-die-vereinbarung-mit-curevac-ueber-die-lieferung-von-bis-zu-405-millionen-dosen-des-mrna-basierten-covid-19-impfstoffkandidaten-cvncov-genehmigen-w/ 2020-11-16T17:57:47+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/european-commission-announces-that-tomorrow-it-will-authorize-the-agreement-with-curevac-for-the-supply-of-up-to-405-million-doses-of-mrna-based-covid-19-vaccine-candidate-cvncov/ 2020-11-16T17:58:17+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-establishes-european-based-network-to-ramp-up-manufacturing-of-its-covid-19-vaccine-candidate-cvncov/ 2020-11-17T12:03:04+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-baut-europaeisches-netzwerk-zur-beschleunigten-produktion-seines-covid-19-impfstoffkandidaten-cvncov-auf/ 2020-11-17T12:03:04+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-und-wacker-unterzeichnen-vertrag-zur-produktion-des-covid-19-impfstoffkandidaten-cvncov-gemeinsame-pressemitteilung/ 2020-11-23T12:11:05+00:00 https://www.curevac.com/en/curevac-and-wacker-sign-manufacturing-contract-for-curevacs-covid-19-vaccine-candidate-cvncov/ 2020-11-23T12:25:22+00:00 https://www.curevac.com/curevac-to-report-third-quarter-and-first-nine-months-2020-financial-results-and-business-updates-on-november-30-2020/ 2020-11-26T13:31:02+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-to-report-third-quarter-and-first-nine-months-2020-financial-results-and-business-updates-on-november-30-2020/ 2020-11-26T13:32:58+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-announces-appointment-of-matthew-l-s-beck-as-vice-president-of-investor-relations/ 2020-11-29T20:47:08+00:00 https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-und-informationen-zur-geschaeftsentwicklung-fuer-das-dritte-quartal-sowie-die-ersten-neun-monate-des-jahres-2020/ 2020-11-30T12:21:12+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-and-business-updates-for-the-third-quarter-and-first-nine-months-of-2020/ 2020-11-30T12:21:45+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-ernennt-antony-blanc-zum-chief-business-officer-und-chief-commercial-officer/ 2020-12-04T12:01:10+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-appoints-antony-blanc-as-chief-business-officer-and-chief-commercial-officer/ 2020-12-04T12:01:42+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/moderne-waerme-im-cyber-valley-stadtwerke-tuebingen-versorgen-neues-produktionsgebaeude-von-curevac/ 2020-12-08T11:02:06+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/12/swtue_190205_Schermaul-Ulrich_kla_001-150x150.jpg https://www.curevac.com/moderne-waerme-im-cyber-valley-stadtwerke-tuebingen-versorgen-neues-produktionsgebaeude-von-curevac-gemeinsame-pressemitteilung/ 2020-12-08T11:10:54+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/12/swtue_190205_Schermaul-Ulrich_kla_001-150x150.jpg https://www.curevac.com/curevac-and-fareva-sign-agreement-for-fill-finish-manufacturing-of-curevacs-covid-19-vaccine-candidate-cvncov/ 2020-12-09T09:00:49+00:00 https://www.curevac.com/en/curevac-and-fareva-sign-agreement-for-fill-finish-manufacturing-of-curevacs-covid-19-vaccine-candidate-cvncov-joint-press-release/ 2020-12-09T09:02:48+00:00 https://www.curevac.com/en/curevac-provides-clinical-update-at-35th-annual-j-p-morgan-healthcare-conference/ 2020-12-14T02:10:10+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/curevac-praesentiert-ergebnisse-klinischer-studien-auf-der-35th-annual-j-p-morgan-healthcare-conference/ 2020-12-14T02:10:35+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/en/curevac-announces-publication-in-the-lancet-of-first-ever-human-proof-of-concept-study-investigating-the-safety-and-immunogenicity-of-a-prophylactic-mrna-vaccine/ 2020-12-14T02:15:50+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/curevac-ag-veroeffentlicht-daten-aus-weltweit-erster-studie-mit-prophylaktischem-mrna-impfstoff/ 2020-12-14T02:17:45+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/en/curevac-announces-first-study-participant-enrolled-in-phase-i-clinical-trial-testing-prophylactic-mrna/ 2020-12-14T02:18:53+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/curevac-verkuendet-den-start-einer-klinischen-phase-i-studie-mit-mrna-basiertem-tollwutimpfstoff/ 2020-12-14T02:19:15+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/en/crispr-therapeutics-and-casebia-collaborate-with-curevac-on-mrna-for-gene-editing-programs/ 2020-12-14T02:20:44+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/crispr-therapeutics-und-casebia-therapeutics-entwickeln-zusammen-mit-curevac-mrna-fuer-crispr-basierte-programme/ 2020-12-14T02:21:01+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/en/curevac-and-arcturus-therapeutics-announce-broad-strategic-collaboration-to-advance-next-generation-of-lipid-mediated-mrna-therapeutics/ 2020-12-14T02:21:45+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/curevac-und-arcturus-therapeutics-verkuenden-eine-umfassende-kooperation-zur-entwicklung-neuartiger-lipid-formulierter-mrna-wirkstoffe/ 2020-12-14T02:22:05+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/en/curevac-to-present-preliminary-phase-i-data-on-cv8102-an-intratumoral-rna-based-cancer-therapy-at-the-2018-society-for-immunotherapy-of-cancer-annual-meeting/ 2020-12-14T02:23:00+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/curevac-praesentiert-vorlaeufige-daten-seiner-phase-i-studie-mit-dem-rna-basierten-wirkstoff-cv8102-zur-intratumoralen-anwendung-auf-der-33-jahrestagung-der-society-for-immunotherapy-of-cancer/ 2020-12-14T02:23:21+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/curevac-erhaelt-us-patent-fuer-mrna-basierte-rsv-impfung-von-saeuglingen/ 2020-12-14T02:24:54+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/en/curevac-announces-u-s-patent-grant-for-mrna-vaccination-of-infants-against-rsv/ 2020-12-14T02:25:14+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/cepi-vergibt-einen-vertrag-ueber-34-millionen-us-dollar-an-curevac-zur-weiteren-entwicklung-des-the-rna-printer/ 2020-12-14T02:26:01+00:00 https://www.curevac.com/en/cepi-awards-us-34m-contract-to-curevac-to-advance-the-rna-printer-a-disruptive-transportable-mrna-vaccine-manufacturing-platform-that-can-rapidly-combat-multiple-diseases/ 2020-12-14T02:26:22+00:00 https://www.curevac.com/curevac-kuendigt-late-breaking-posterpraesentation-mit-neuesten-daten-anlaesslich-der-jahreskonferenz-2019-der-american-association-of-cancer-research-aacr-an/ 2020-12-14T02:27:20+00:00 https://www.curevac.com/en/curevac-announces-late-breaking-poster-presentation-at-american-association-of-cancer-research-aacr-annual-meeting-2019/ 2020-12-14T02:27:40+00:00 https://www.curevac.com/zwei-neue-aufsichtsratsmitglieder-bei-curevac/ 2020-12-14T02:28:45+00:00 https://www.curevac.com/en/curevac-welcomes-two-members-to-its-supervisory-board/ 2020-12-14T02:29:03+00:00 https://www.curevac.com/curevac-schliesst-exklusive-forschungskooperation-mit-der-yale-universitaet-zur-erforschung-mrna-basierter-arzneimittelkandidaten-fuer-die-behandlung-von-lungenerkrankungen/ 2020-12-14T02:29:38+00:00 https://www.curevac.com/en/curevac-enters-into-an-exclusive-collaborative-research-agreement-for-discovery-research-in-mrna-based-lung-therapy-candidates-with-yale-university/ 2020-12-14T02:29:58+00:00 https://www.curevac.com/curevac-praesentiert-daten-zu-cv8102-auf-sitc-konferenz/ 2020-12-14T02:30:28+00:00 https://www.curevac.com/en/curevac-to-present-cv8102-data-at-sitc-conference/ 2020-12-14T02:30:47+00:00 https://www.curevac.com/curevac-praesentiert-auf-31-annual-piper-jaffray-healthcare-conference/ 2020-12-14T02:31:31+00:00 https://www.curevac.com/en/curevac-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference/ 2020-12-14T02:31:50+00:00 https://www.curevac.com/curevac-und-cepi-bauen-ihre-kooperation-zur-entwicklung-eines-impfstoffs-gegen-das-coronavirus-ncov-2019-aus/ 2020-12-14T02:34:31+00:00 https://www.curevac.com/en/curevac-and-cepi-extend-their-cooperation-to-develop-a-vaccine-against-coronavirus-ncov-2019/ 2020-12-14T02:34:58+00:00 https://www.curevac.com/en/bundesregierung-beteiligt-sich-mit-300-millionen-euro-an-curevac/ 2020-12-14T02:36:10+00:00 https://www.curevac.com/bundesregierung-beteiligt-sich-mit-300-millionen-euro-an-curevac/ 2020-12-14T02:36:36+00:00 https://www.curevac.com/en/please-note-currently-there-is-no-possibility-to-purchase-shares-of-curevac-ag-offers-to-purchase-shares-in-curevac-ag-are-fraudulent/ 2020-12-14T02:37:37+00:00 https://www.curevac.com/bitte-beachten-sie-derzeit-gibt-es-keine-moeglichkeit-aktien-der-curevac-ag-zu-erwerben-angebote-zum-kauf-von-aktien-der-curevac-ag-die-ihnen-gemacht-werden-sind-betruegerischer-natur/ 2020-12-14T02:37:55+00:00 https://www.curevac.com/en/germany-eib-and-european-commission-provide-curevac-with-a-e75-million-financing-for-vaccine-development-and-expansion-of-manufacturing/ 2020-12-14T02:38:38+00:00 https://www.curevac.com/die-eib-und-europaeische-kommission-stellen-curevac-finanzmittel-in-hoehe-von-75-mio-eur-fuer-die-entwicklung-und-ausweitung-der-produktion-von-impfstoffen-zur-verfuegung/ 2020-12-14T02:39:09+00:00 https://www.curevac.com/en/gsk-and-curevac-announce-strategic-mrna-technology-collaboration/ 2020-12-14T02:39:51+00:00 https://www.curevac.com/gsk-und-curevac-verkuenden-strategische-mrna-technologiepartnerschaft/ 2020-12-14T02:40:23+00:00 https://www.curevac.com/en/curevac-raises-a-total-of-usd-640-million-in-private-financing-round/ 2020-12-14T02:41:09+00:00 https://www.curevac.com/curevac-erhaelt-640-millionen-dollar-in-privater-finanzierungsrunde/ 2020-12-14T02:41:31+00:00 https://www.curevac.com/en/curevac-appoints-dr-franz-werner-haas-as-chief-executive-officer-and-dr-igor-splawski-as-chief-scientific-officer/ 2020-12-14T02:42:13+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/curevac-ernennt-dr-franz-werner-haas-zum-chief-executive-officer-dr-igor-splawski-wird-chief-scientific-officer/ 2020-12-14T02:42:38+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/en/curevac-announces-proposed-initial-public-offering-of-common-shares/ 2020-12-14T02:43:21+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/curevac-kuendigt-geplante-erstemission-von-stammaktien-an/ 2020-12-14T02:43:51+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/en/curevac-announces-pricing-of-initial-public-offering/ 2020-12-14T02:45:47+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/curevac-kuendigt-preis-fuer-erstemission-von-stammaktien-an/ 2020-12-14T02:46:21+00:00 https://www.curevac.com/wp-content/uploads/2020/06/CureVac_Thorsten-Sch%C3%BCller_2-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/06/sarah-fakih-150x150.jpg https://www.curevac.com/curevac-und-die-universitaetsmedizin-mainz-starten-klinische-phase-3-studie-fuer-covid-19-impfstoffkandidaten-cvncov-an-mitarbeitern-im-gesundheitswesen/ 2020-12-21T06:00:04+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/ 2020-12-21T06:00:21+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-und-bayer-arbeiten-gemeinsam-an-covid-19-impfstoffkandidaten-cvncov/ 2021-01-07T19:25:48+00:00 https://www.curevac.com/en/curevac-and-bayer-join-forces-on-covid-19-vaccine-candidate-cvncov/ 2021-01-07T19:27:18+00:00 https://www.curevac.com/covid-19-impfstoffkandidat-cvncov-von-curevac-zeigt-effizienten-schutz-vor-einer-sars-cov-2-infektion-bei-nichtmenschlichen-primaten/ 2021-01-11T12:00:10+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-of-non-human-primates-during-sars-cov-2-challenge-infection/ 2021-01-11T12:00:34+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-kuendigt-geplantes-angebot-von-stammaktien-an/ 2021-01-25T21:23:18+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/en/curevac-announces-proposed-public-offering-of-common-shares/ 2021-01-25T21:24:14+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/curevac-kuendigt-kapitalerhoehung-von-450-millionen-us-dollar-an/ 2021-01-28T06:00:21+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/en/curevac-announces-pricing-of-450-million-follow-on-public-offering-of-common-shares/ 2021-01-28T06:00:40+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/curevac-und-rentschler-biopharma-fahren-herstellung-von-covid-19-impfstoff-cvncov-hoch/ 2021-02-02T09:26:19+00:00 https://www.curevac.com/en/curevac-and-rentschler-biopharma-ramp-up-manufacturing-of-covid-19-vaccine-cvncov/ 2021-02-02T09:27:52+00:00 https://www.curevac.com/curevac-kuendigt-den-abschluss-des-oeffentlichen-zeichnungsangebots-mit-einem-erloes-von-450-millionen-us-dollar-an/ 2021-02-03T11:52:01+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/en/curevac-announces-closing-of-450-million-follow-on-public-offering-of-common-shares/ 2021-02-03T11:52:16+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/gsk-und-curevac-entwickeln-mrna-impfstoff-der-naechsten-generation-gegen-covid-19/ 2021-02-03T13:46:35+00:00 https://www.curevac.com/en/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/ 2021-02-03T13:52:18+00:00 https://www.curevac.com/curevac-kuendigt-die-vollstaendige-ausuebung-der-option-der-zeichner-zum-kauf-weiterer-stammaktien-an/ 2021-02-04T12:04:36+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/en/curevac-announces-full-exercise-of-underwriters-option-to-purchase-additional-common-shares/ 2021-02-04T12:05:20+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/curevac-erweitert-phase-1-studie-seines-rna-kandidaten-cv8102-beim-fortgeschrittenen-melanom/ 2021-02-04T12:13:16+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-expands-lead-rna-cancer-program-phase-1-trial-in-advanced-melanoma/ 2021-02-04T12:13:53+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-and-uk-government-to-collaborate-on-development-of-vaccines-against-sars-cov-2-variants/ 2021-02-05T12:01:22+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-veranstaltet-am-5-februar-2021-eine-telefonkonferenz-zum-stand-der-covid-19-partnerschaften/ 2021-02-05T12:17:12+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-to-host-conference-call-on-covid-19-partnership-update-on-february-5-2021/ 2021-02-05T12:17:12+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-kooperiert-mit-britischer-regierung-bei-der-entwicklung-von-impfstoffen-gegen-sars-cov-2-varianten/ 2021-02-05T12:39:51+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-startet-rollierendes-zulassungsverfahren-bei-europaeischer-arzneimittelagentur-fuer-covid-19-impfstoffkandidaten-cvncov/ 2021-02-12T10:03:00+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-initiates-rolling-submission-with-european-medicines-agency-for-covid-19-vaccine-candidate-cvncov/ 2021-02-12T10:03:40+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-gibt-teilnahme-an-kommenden-investoren-konferenzen-bekannt/ 2021-02-18T12:00:47+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/en/curevac-to-participate-in-upcoming-investor-conferences-2/ 2021-02-18T12:01:10+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/curevac-und-novartis-unterzeichnen-initiale-vereinbarung-zur-produktion-des-covid-19-impfstoffkandidaten-cvncov/ 2021-03-04T12:00:12+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-and-novartis-sign-initial-agreement-on-manufacturing-of-covid-19-vaccine-candidate-cvncov/ 2021-03-04T12:00:42+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-erweitert-analyse-der-klinischen-studie-fuer-covid-19-impfstoffkandidaten-cvncov-um-phase-2b-3-varianten-spezifikation-und-sekundaeren-wirksamkeitsendpunkt-bei-phase-2a/ 2021-03-22T12:21:49+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-expands-cvncov-covid-19-vaccine-candidate-clinical-trial-analyses-to-include-phase-2b-3-variant-specification-and-efficacy-secondary-endpoint-to-phase-2a/ 2021-03-22T12:25:37+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevacs-covid-19-vaccine-candidate-cvncov-demonstrates-protection-against-sars-cov-2-b-1-351-variant-south-african-variant-in-preclinical-challenge-study/ 2021-03-24T09:45:06+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevacs-covid-19-impfstoffkandidat-cvncov-zeigt-in-praeklinischer-challenge-studie-schutzwirkung-gegen-virusvariante-b-1-351-suedafrika-variante-von-sars-cov-2/ 2021-03-24T09:46:05+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/celonic-and-curevac-announce-agreement-to-manufacture-over-100-million-doses-of-curevacs-covid-19-vaccine-candidate-cvncov/ 2021-03-30T11:00:14+00:00 https://www.curevac.com/en/celonic-and-curevac-announce-agreement-to-manufacture-over-100-million-doses-of-curevacs-covid-19-vaccine-candidate-cvncov/ 2021-03-30T11:00:44+00:00 https://www.curevac.com/curevac-veroeffentlicht-am-15-april-2021-finanzergebnisse-des-vierten-quartals-sowie-des-gesamtjahres-2020-und-informiert-ueber-seine-geschaeftsentwicklung/ 2021-04-09T11:42:23+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-to-report-fourth-quarter-and-full-year-2020-financial-results-and-business-updates-on-april-15-2021/ 2021-04-09T13:01:09+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-and-business-updates-for-the-fourth-quarter-and-full-year-of-2020/ 2021-04-15T11:30:50+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-des-vierten-quartals-sowie-des-gesamtjahres-2020-und-informiert-ueber-seine-geschaeftsentwicklung/ 2021-04-15T14:02:11+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-swiss-ag-startet-rollendes-zulassungsverfahren-bei-swissmedic-fuer-mrna-basierten-covid-19-impfstoffkandidaten-cvncov/ 2021-04-19T11:00:10+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-swiss-ag-initiates-rolling-submission-process-for-mrna-based-covid-19-vaccine-candidate-cvncov-with-swissmedic/ 2021-04-19T11:00:43+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/covid-19-impfstoffkandidat-der-zweiten-generation-cv2cov-zeigt-hohe-immunogenitaet-gegen-virusmutationen-in-praeklinischer-studie/ 2021-05-14T06:05:23+00:00 https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/second-generation-covid-19-vaccine-candidate-cv2cov-demonstrates-high-immunogenicity-against-virus-variants-in-preclinical-study/ 2021-05-14T06:06:02+00:00 https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-des-ersten-quartals-2021-und-informiert-ueber-seine-geschaeftsentwicklung/ 2021-05-28T17:26:49+00:00 https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-first-quarter-of-2021-and-business-updates/ 2021-05-28T17:27:14+00:00 https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevacs-impfstoffkandidat-der-ersten-generation-cvncov-setzt-nach-dsmb-empfehlung-in-phase-2b-3-wirksamkeitsnachweis-in-variantengepraegtem-umfeld-fort/ 2021-06-02T10:17:22+00:00 https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevacs-first-generation-covid-19-vaccine-candidate-cvncov-continues-toward-phase-2b-3-efficacy-readout-in-variant-rich-environment-following-dsmb-recommendation/ 2021-06-02T10:18:24+00:00 https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-ernennt-klaus-edvardsen-zum-chief-development-officer/ 2021-06-02T11:00:09+00:00 https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-appoints-klaus-edvardsen-as-chief-development-officer/ 2021-06-02T11:00:59+00:00 https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov/ 2021-06-11T06:22:25+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/curevac-beginnt-die-globale-zulassungsrelevante-phase-2b-3-studie-fuer-seinen-covid-19-impfstoffkandidaten-cvncov/ 2021-06-11T06:23:23+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Thorsten-Schueller_Vice-President-Communications-150x150.jpg https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/en/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/ 2021-06-17T12:31:11+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-gibt-status-update-zur-phase-2b-3-studie-fuer-impfstoffkandidat-der-ersten-generation-cvncov-bekannt/ 2021-06-17T12:32:00+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-gibt-personelle-aenderungen-im-aufsichtsrat-bekannt/ 2021-06-23T11:30:24+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-provides-supervisory-board-update/ 2021-06-23T11:30:42+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/english-only-curevac-announces-voting-results-of-general-meeting/ 2021-06-24T20:15:06+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-announces-voting-results-of-general-meeting/ 2021-06-24T20:15:23+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-gibt-ernennung-von-dr-malte-greune-zum-chief-operating-officer-und-den-funktionswechsel-von-dr-florian-von-der-muelbe-zur-beschleunigten-weiterentwicklung-des-the-rna-printer-bekannt/ 2021-06-30T11:00:17+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-announces-appointment-of-dr-malte-greune-as-chief-operating-officer-and-transition-of-dr-florian-von-der-muelbe-to-lead-accelerated-development-of-the-rna-printer/ 2021-06-30T11:00:41+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-final-data-from-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov-demonstrates-protection-in-age-group-of-18-to-60/ 2021-06-30T20:30:32+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevacs-daten-der-finalen-analyse-der-phase-2b-3-studie-fuer-cvncov-den-impfstoffkandidaten-der-ersten-generation-zeigen-schutzwirkung-in-altersgruppe-von-18-bis-60-jahren/ 2021-07-01T09:47:13+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-des-zweiten-quartals-und-ersten-halbjahres-2021-und-informiert-ueber-seine-geschaeftsentwicklung/ 2021-08-16T11:10:03+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-second-quarter-and-first-half-of-2021-and-provides-business-update/ 2021-08-16T11:10:19+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/mrna-basierter-covid-19-impfstoffkandidat-der-zweiten-generation-cv2cov-zeigt-verbesserte-immunantwort-und-schutzwirkung-in-praeklinischer-studie/ 2021-08-16T15:05:44+00:00 https://www.curevac.com/en/second-generation-mrna-covid-19-vaccine-candidate-cv2cov-demonstrates-improved-immune-response-and-protection-in-preclinical-study/ 2021-08-16T15:06:51+00:00 https://www.curevac.com/curevac-studie-praeklinische-daten-zeigen-deutliche-verminderung-von-leberfibrose-mit-mrna-therapeutikum/ 2021-08-30T11:00:10+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-preclinical-data-demonstrates-significant-reduction-of-liver-fibrosis-with-mrna-therapeutic/ 2021-08-30T11:00:34+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-streamlines-european-network-for-mrna-product-manufacturing/ 2021-09-14T11:14:34+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-verlagert-fokus-der-covid-19-impfstoffentwicklung-auf-mrna-technologie-der-zweiten-generation/ 2021-10-12T11:03:06+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-to-shift-focus-of-covid-19-vaccine-development-to-second-generation-mrna-technology/ 2021-10-13T10:33:41+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-verschlankt-europaeisches-netzwerk-zur-mrna-produktherstellung/ 2021-10-13T16:46:59+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-praesentiert-daten-auf-sitc-konferenz-aus-phase-1-studie-von-onkologie-kandidat-cv8102-die-systemische-immunantwort-zeigen/ 2021-11-10T12:00:17+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-presents-promising-data-at-sitc-from-phase-1-study-of-oncology-candidate-cv8102-showing-systemic-immune-response/ 2021-11-10T12:00:45+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevacs-cvncov-phase-2b-3-study-data-published-in-preprints-with-the-lancet/ 2021-11-17T13:17:57+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevacs-phase-2b-3-studiendaten-fuer-cvncov-auf-pre-print-server-the-lancet-veroeffentlicht/ 2021-11-17T13:18:50+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-in-nature-praeklinische-daten-des-covid-19-kandidaten-der-zweiten-generation-cv2cov-die-vergleichbaren-antikoerperspiegel-wie-bei-lizenziertem-mrna-impfstof/ 2021-11-18T10:45:02+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-publishes-in-nature-preclinical-data-of-second-generation-covid-19-candidate-cv2cov-demonstrating-comparable-antibody-levels-to-licensed-mrna-vaccine/ 2021-11-18T10:45:28+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-dritte-quartal-sowie-die-ersten-neun-monate-2021-und-informiert-ueber-das-laufende-geschaeft/ 2021-11-18T21:10:25+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-third-quarter-and-first-nine-months-of-2021-and-provides-business-update/ 2021-11-18T21:10:25+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Anna-Kamilli-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-chief-technology-officer-verfolgt-neue-karriere-ausserhalb-der-biotech-branche/ 2022-01-17T12:00:13+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-chief-technology-officer-to-pursue-new-career-outside-biotech-industry/ 2022-01-17T12:00:38+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-gibt-erste-impfung-von-proband-in-phase-1-studie-mit-multivalentem-grippeimpfstoff-kandidaten-auf-basis-des-mrna-rueckgrats-der-zweiten-generation-bekannt-impfstoffkandidat-gemeinsam/ 2022-02-10T12:00:56+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-doses-first-participant-in-phase-1-study-with-multivalent-influenza-vaccine-candidate-based-on-second-generation-mrna-backbone-developed-in-collaboration-with-gsk/ 2022-02-10T12:00:56+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-establishes-fully-owned-company-dedicated-to-advancing-the-rna-printer/ 2022-03-01T12:01:06+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printers/ 2022-03-07T18:29:21+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-and-gsk-start-clinical-development-of-second-generation-covid-19-vaccine-candidate-cv2cov/ 2022-03-30T11:01:27+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-und-gsk-starten-klinische-entwicklung-des-covid-19-impfstoffkandidaten-der-zweiten-generation-cv2cov/ 2022-03-30T11:26:13+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-und-gsk-schliessen-vertrag-mit-der-deutschen-bundesregierung-zur-pandemievorsorge-ab/ 2022-04-11T11:00:16+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-and-gsk-enter-into-pandemic-preparedness-contract-with-german-government/ 2022-04-11T11:01:14+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-and-gsks-bivalent-second-generation-mrna-vaccine-candidate-shown-to-be-highly-effective-against-sars-cov-2-variants-in-preclinical-study/ 2022-04-21T11:00:53+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevacs-und-gsks-bivalenter-mrna-impfstoffkandidat-der-zweiten-generation-zeigt-hohe-wirksamkeit-gegen-sars-cov-2-varianten-in-praeklinischer-studie/ 2022-04-21T15:38:08+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-am-28-april-2022-finanzergebnisse-des-vierten-quartals-sowie-des-gesamtjahres-2021-und-informiert-ueber-seine-geschaeftsentwicklung/ 2022-04-22T11:00:19+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-to-report-fourth-quarter-and-full-year-2021-financial-results-and-business-updates-on-april-28-2022/ 2022-04-22T11:01:00+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-vierte-quartal-sowie-das-gesamtjahr-2021-und-informiert-ueber-seine-geschaeftsentwicklung/ 2022-04-28T11:00:13+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-fourth-quarter-and-full-year-2021-and-provides-business-update/ 2022-04-28T11:01:51+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-arbeitet-mit-myneo-zusammen-zur-identifikation-neuartiger-antigene-fuer-die-entwicklung-mrna-basierter-krebsimpfstoffe/ 2022-05-25T11:00:41+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-partners-with-myneo-to-identify-novel-antigen-targets-for-mrna-based-cancer-vaccine-development/ 2022-05-25T11:01:16+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-erste-quartal-2022-und-informiert-ueber-seine-geschaeftsentwicklung/ 2022-05-25T11:05:51+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-first-quarter-of-2022-and-provides-business-update/ 2022-05-25T11:06:24+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-besetzt-die-stelle-des-chief-development-officers-neu-myriam-mendila-folgt-auf-klaus-edvardsen/ 2022-06-08T20:05:13+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-announces-changes-of-cdo-myriam-mendila-to-succeed-klaus-edvardsen/ 2022-06-08T20:05:54+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-beschleunigt-onkologie-strategie-mit-uebernahme-von-frame-cancer-therapeutics-und-fuegt-neuartige-antigen-entdeckungsplattform-hinzu/ 2022-06-08T20:10:11+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-accelerates-oncology-strategy-with-acquisition-of-frame-cancer-therapeutics-adding-novel-antigen-discovery-platform/ 2022-06-08T20:10:38+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/english-only-curevac-announces-voting-results-of-general-meeting-2/ 2022-06-22T20:05:19+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/en/curevac-announces-voting-results-of-general-meeting-2/ 2022-06-22T20:06:27+00:00 https://www.curevac.com/wp-content/uploads/2020/11/CureVac_Dr.-Sarah-Fakih_Vice-President-Investor-Relations-150x150.jpg https://www.curevac.com/wp-content/uploads/2021/05/Joedicke04_lowres-150x150.jpg https://www.curevac.com/curevac-reicht-in-deutschland-klage-gegen-biontech-wegen-patentrechtsverletzung-ein/ 2022-07-05T11:01:03+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-files-patent-infringement-lawsuit-in-germany-against-biontech/ 2022-07-05T11:01:42+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-beginnt-mit-klinischer-phase-1-studie-fuer-modifizierten-covid-19-impfstoffkandidaten-gegen-omikron-variante/ 2022-08-18T11:03:06+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-starts-phase-1-clinical-study-of-modified-omicron-targeting-covid-19-vaccine-candidate/ 2022-08-18T11:03:39+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-zweite-quartal-und-erste-halbjahr-2022-und-informiert-ueber-seine-geschaeftsentwicklung/ 2022-08-19T08:27:42+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-second-quarter-and-first-half-of-2022-and-provides-business-update/ 2022-08-19T08:29:56+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-vorlaeufige-daten-der-phase-1-erweiterungsstudie-mit-onkologie-kandidaten-cv8102/ 2022-11-11T12:00:09+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-presents-preliminary-data-from-phase-1-study-expansion-of-oncology-candidate-cv8102/ 2022-11-11T12:00:49+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-dritte-quartal-sowie-die-ersten-neun-monate-2022-und-informiert-ueber-seine-geschaeftsentwicklung/ 2022-11-16T12:00:25+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-third-quarter-of-2022-and-first-nine-months-of-2022-and-provides-business-update/ 2022-11-16T12:04:33+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-mitglieder-der-geschaeftsleitung-verkaufen-aktien-zur-deckung-steuerlicher-verpflichtungen-aus-long-term-incentive-programm/ 2022-12-14T21:05:21+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-members-of-management-sell-shares-to-cover-tax-obligations-from-long-term-incentive-program/ 2022-12-14T21:05:54+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-gibt-positive-daten-aus-gemeinsamen-covid-19-und-grippe-mrna-impfstoffentwicklungsprogrammen-bekannt/ 2023-01-06T12:01:35+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-positive-data-on-joint-covid-19-and-flu-mrna-vaccine-development-programs/ 2023-01-06T13:12:01+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-ernennt-alexander-zehnder-zum-vorstandsvorsitzenden-ab-1-april-2023/ 2023-01-09T12:00:15+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-appoints-alexander-zehnder-as-ceo-from-april-1-2023/ 2023-01-10T10:53:31+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-positive-daten-bei-aelteren-erwachsenen-aus-covid-19-und-grippe-mrna-impfstoffentwicklungsprogrammen/ 2023-01-30T12:02:05+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-positive-data-in-older-adults-from-covid-19-and-flu-mrna-vaccine-development-programs/ 2023-01-30T12:03:12+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-von-lexisnexis-als-einer-der-weltweit-dynamischsten-innovatoren-ausgezeichnet/ 2023-01-31T13:12:28+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-named-as-one-of-the-worlds-most-dynamic-innovators-by-lexisnexis/ 2023-01-31T13:13:24+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-begruesst-dr-myriam-mendila-als-neuen-chief-development-officer/ 2023-02-01T12:00:57+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-welcomes-myriam-mendila-as-new-chief-development-officer/ 2023-02-01T12:01:31+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-kuendigt-geplantes-angebot-von-stammaktien-an-2/ 2023-02-06T21:09:05+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-proposed-public-offering-of-common-shares-2/ 2023-02-06T21:10:56+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-gibt-preisgestaltung-des-erhoehten-oeffentlichen-angebots-von-stammaktien-bekannt/ 2023-02-08T01:04:22+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-pricing-of-upsized-public-offering-of-common-shares/ 2023-02-08T01:04:57+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-gibt-abschluss-des-oeffentlichen-zeichnungsangebots-mit-erloes-von-250-millionen-us-dollar-bekannt/ 2023-02-10T21:05:10+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-closing-of-250-million-follow-on-public-offering-of-common-shares/ 2023-02-10T21:05:36+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-to-report-third-quarter-and-first-nine-months-2022-financial-results-and-business-updates-on-november-16-2022/ 2023-03-01T19:01:58+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-am-16-november-2022-finanzergebnisse-des-dritten-quartals-sowie-der-ersten-neun-monate-2022-und-informiert-ueber-seine-geschaeftsentwicklung/ 2023-03-01T19:02:48+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-announces-voting-results-of-extraordinary-general-meeting/ 2023-04-12T11:15:47+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-voting-results-of-extraordinary-general-meeting/ 2023-04-12T11:20:22+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-am-25-april-2023-finanzergebnisse-des-vierten-quartals-sowie-des-gesamtjahres-2022-und-informiert-ueber-seine-geschaeftsentwicklung/ 2023-04-18T11:00:16+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-to-report-fourth-quarter-and-full-year-2022-financial-results-and-business-updates-on-april-25-2023/ 2023-04-18T11:00:41+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-vierte-quartal-sowie-das-gesamtjahr-2022-und-informiert-ueber-seine-geschaeftsentwicklung/ 2023-04-25T11:00:17+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-fourth-quarter-and-full-year-2022-and-provides-business-update/ 2023-04-25T11:00:41+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-gibt-impfung-des-ersten-teilnehmers-in-kombinierter-phase-1-2-studie-fuer-multivalente-modifizierte-grippe-impfstoffkandidaten-bekannt-entwickelt-in-zusammenarbeit-mit-gsk/ 2023-05-08T11:00:25+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-dosing-of-first-participant-in-combined-phase-1-2-study-of-multivalent-modified-influenza-vaccine-candidates-developed-in-collaboration-with-gsk/ 2023-05-08T11:04:58+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2022/07/2022_03_30_CureVac_Bettina5022b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-developments-in-patent-litigation-with-pfizer-biontech/ 2023-05-19T11:00:52+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-gibt-entwicklungen-im-patentrechtsstreit-mit-pfizer-biontech-bekannt/ 2023-05-30T08:09:36+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-erste-quartal-2023-und-informiert-ueber-seine-geschaeftsentwicklung/ 2023-05-30T11:00:45+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-first-quarter-of-2023-and-provides-business-update/ 2023-05-30T11:36:31+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-voting-results-of-general-meeting-3/ 2023-06-19T15:33:37+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-announces-voting-results-of-general-meeting/ 2023-06-19T15:33:37+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-beruft-internationalen-finanzexperten-michael-brosnan-in-den-aufsichtsrat/ 2023-06-20T11:03:26+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-appoints-international-financial-expert-michael-brosnan-to-supervisory-board/ 2023-06-20T11:05:23+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-behandelt-ersten-patienten-in-phase-1-studie-mit-krebsimpfstoffkandidat-fuer-operativ-reseziertes-glioblastom/ 2023-06-20T11:33:57+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-doses-first-patient-in-phase-1-study-of-cancer-vaccine-candidate-for-surgically-resected-glioblastoma/ 2023-06-20T11:34:54+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-staerkt-position-in-laufenden-patentrechtsverfahren-durch-zusaetzliche-schutzrechte/ 2023-07-13T11:32:52+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-strengthens-ongoing-patent-litigations-bringing-additional-cases-under-new-intellectual-property-rights/ 2023-07-13T12:22:08+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-gibt-update-im-management-team-bekannt/ 2023-07-14T11:10:22+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-update-to-the-management-team/ 2023-07-14T11:10:22+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-dosing-of-first-participant-in-phase-2-study-of-modified-covid-19-mrna-vaccine-candidates-developed-in-collaboration-with-gsk/ 2023-08-01T11:02:37+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-gibt-impfung-des-ersten-teilnehmers-in-phase-2-studie-fuer-modifizierte-covid-19-mrna-impfstoffkandidaten-bekannt-die-in-zusammenarbeit-mit-gsk-entwickelt-werden/ 2023-08-01T11:03:03+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-zweite-quartal-und-erste-halbjahr-2023-und-informiert-ueber-seine-geschaeftsentwicklung/ 2023-08-17T11:00:37+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-second-quarter-and-first-half-of-2023-and-provides-business-update/ 2023-08-17T11:00:50+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-geht-in-phase-2-der-laufenden-saisonalen-grippestudie-in-zusammenarbeit-mit-gsk-nach-auswahl-eines-vielversprechenden-mrna-impfstoffkandidaten-mit-breiter-abdeckung/ 2023-09-12T11:00:27+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-advances-seasonal-flu-study-to-phase-2-in-collaboration-with-gsk-following-selection-of-promising-mrna-vaccine-candidate-with-broad-coverage/ 2023-09-12T11:00:42+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-berichtet-ueber-fortschritt-im-verfahren-der-verletzung-geistigen-eigentums-gegen-biontech-in-deutschland/ 2023-09-28T11:00:15+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-reports-progress-in-intellectual-property-infringement-case-against-biontech-in-germany/ 2023-09-28T12:38:10+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-to-report-third-quarter-and-first-nine-months-2023-financial-results-and-business-updates-on-november-14-2023/ 2023-10-31T15:18:41+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-meldet-fortschritte-in-klinischen-phase-2-entwicklungsprogrammen-fuer-covid-19-und-die-saisonale-grippe-in-zusammenarbeit-mit-gsk/ 2023-11-01T12:00:25+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-solid-progress-in-phase-2-covid-19-and-seasonal-flu-clinical-development-programs-in-collaboration-with-gsk/ 2023-11-01T12:01:08+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-dritte-quartal-sowie-die-ersten-neun-monate-2023-und-informiert-ueber-seine-geschaeftsentwicklung/ 2023-11-14T12:00:07+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-third-quarter-and-first-nine-months-of-2023-and-provides-business-update/ 2023-11-14T12:00:26+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-gibt-urteil-des-bundespatentgerichts-zur-patentgueltigkeit-in-breitem-patentstreit-mit-biontech-se-bekannt/ 2023-12-19T14:23:08+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-decision-of-german-federal-patent-court-in-broad-patent-litigation-with-biontech-se/ 2023-12-19T14:23:14+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-am-14-november-2023-finanzergebnisse-des-dritten-quartals-sowie-der-ersten-neun-monate-2023-und-informiert-ueber-seine-geschaeftsentwicklung/ 2024-01-04T15:45:27+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-positive-interim-phase-2-daten-des-covid-19-impfstoff-entwicklungsprogramms-in-zusammenarbeit-mit-gsk-die-starke-validierung-der-firmeneigenen-technologie-plattform-belegen/ 2024-01-05T12:00:25+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-positive-phase-2-interim-data-from-covid-19-vaccine-development-program-in-collaboration-with-gsk-providing-strong-validation-of-proprietary-technology-platform/ 2024-01-05T12:00:48+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/form-6-k-only-english-only-curevac-ceo-alexander-zehnder-acquires-common-shares-of-company-stock/ 2024-03-20T15:49:48+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/form-6-k-only-english-only-curevac-ceo-alexander-zehnder-acquires-common-shares-of-company-stock/ 2024-03-20T15:50:42+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-gibt-vielversprechende-interim-phase-2-daten-aus-entwicklungsprogramm-fuer-saisonalen-grippeimpfstoff-in-zusammenarbeit-mit-gsk-bekannt/ 2024-04-04T11:00:06+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-announces-promising-phase-2-interim-data-from-seasonal-influenza-vaccine-development-program-in-collaboration-with-gsk/ 2024-04-04T11:37:24+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-and-md-anderson-enter-strategic-collaboration-to-develop-novel-cancer-vaccines/ 2024-04-16T11:00:37+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-und-md-anderson-gehen-strategische-kooperation-zur-entwicklung-neuartiger-krebsimpfstoffe-ein/ 2024-04-16T11:00:37+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-veroeffentlicht-am-24-april-2024-finanzergebnisse-des-vierten-quartals-sowie-des-gesamtjahres-2023-und-informiert-ueber-seine-geschaeftsentwicklung/ 2024-04-18T11:11:15+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-to-report-fourth-quarter-and-full-year-2023-financial-results-and-business-update-on-april-24-2024/ 2024-04-18T11:11:45+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-ernennt-thaminda-ramanayake-zum-neuen-chief-business-officer/ 2024-04-24T11:00:12+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-gibt-start-einer-kombinierten-phase-1-2-studie-zur-vogelgrippe-h5n1-bekannt-entwicklung-in-zusammenarbeit-mit-gsk/ 2024-04-24T11:03:25+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-vierte-quartal-sowie-das-gesamtjahr-2023-und-informiert-ueber-seine-geschaeftsentwicklung/ 2024-04-24T11:08:47+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-announces-financial-results-for-the-fourth-quarter-and-full-year-2023-and-provides-business-update/ 2024-04-24T11:23:28+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-announces-start-of-combined-phase-1-2-study-in-avian-influenza-h5n1-development-in-collaboration-with-gsk/ 2024-04-24T11:23:56+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-appoints-thaminda-ramanayake-as-new-chief-business-officer/ 2024-04-24T11:24:21+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-announces-financial-results-for-the-first-quarter-of-2024-and-provides-business-update/ 2024-05-23T11:02:30+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-erste-quartal-2024-und-informiert-ueber-seine-geschaeftsentwicklung/ 2024-05-23T11:02:42+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-announces-dosing-of-first-participant-in-a-phase-2-study-in-seasonal-influenza-development-in-collaboration-with-gsk/ 2024-05-28T11:02:41+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-gibt-impfung-des-ersten-teilnehmers-in-einer-phase-2-studie-zur-saisonalen-grippe-bekannt-entwicklung-in-zusammenarbeit-mit-gsk/ 2024-05-28T11:02:41+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/english-only-curevac-announces-voting-results-of-general-meeting-3/ 2024-06-24T20:26:06+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/english-only-curevac-announces-voting-results-of-general-meeting/ 2024-06-24T20:26:40+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement/ 2024-07-03T06:11:26+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/gsk-und-curevac-restrukturieren-zusammenarbeit-in-eine-neue-lizenzvereinbarung/ 2024-07-03T06:11:37+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-startet-strategische-umstrukturierung-um-ressourcen-auf-hochwertige-mrna-pipeline-moeglichkeiten-auszurichten/ 2024-07-09T09:32:42+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-initiates-strategic-restructuring-to-align-resources-with-focus-on-high-value-mrna-pipeline-opportunities/ 2024-07-09T09:33:14+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-provides-update-on-trial-dates-for-patent-litigation-across-multiple-geographies-against-pfizer-biontech/ 2024-07-11T11:02:58+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-gibt-update-ueber-verhandlungstermine-im-patentrechtsstreit-gegen-pfizer-biontech-in-mehreren-regionen-bekannt/ 2024-07-11T11:02:58+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-names-oncologist-and-drug-development-expert-dr-mehdi-shahidi-to-supervisory-board/ 2024-08-15T11:02:22+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-beruft-den-onkologen-und-experten-fuer-medikamentenentwicklung-dr-mehdi-shahidi-in-den-aufsichtsrat/ 2024-08-15T11:02:35+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/curevac-startet-teil-b-von-phase-1-studie-mit-krebsimpfstoff-kandidaten-cvgbm-bei-patienten-mit-reseziertem-glioblastom/ 2024-08-15T11:05:14+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-advances-cancer-vaccine-candidate-cvgbm-to-part-b-of-phase-1-study-in-patients-with-resected-glioblastoma/ 2024-08-15T11:05:25+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-announces-financial-results-for-the-second-quarter-and-first-half-of-2024-and-provides-business-update/ 2024-08-15T11:08:32+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-to-present-first-cvgbm-glioblastoma-cancer-vaccine-clinical-data-at-esmo-2024-congress/ 2024-09-09T11:11:38+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-praesentiert-erste-klinische-daten-zu-cvgbm-glioblastom-krebsimpfung-auf-dem-esmo-kongress-2024/ 2024-09-09T11:11:38+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-partner-gsk-announces-positive-phase-2-data-from-seasonal-influenza-mrna-vaccine-program/ 2024-09-12T11:35:25+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-partner-gsk-gibt-positive-phase-2-daten-aus-saisonalem-mrna-grippeimpfstoffprogramm-bekannt/ 2024-09-12T11:35:35+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevacs-cvgbm-cancer-vaccine-induces-promising-immune-responses-in-phase-1-study-in-glioblastoma-presented-at-the-esmo-2024-congress/ 2024-09-16T12:49:18+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-cvgbm-krebsimpfstoff-induziert-vielversprechende-immunantworten-in-phase-1-studie-beim-glioblastom-praesentation-auf-dem-esmo-kongress-2024/ 2024-09-16T12:51:30+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-to-present-at-the-12th-international-mrna-health-conference/ 2024-11-04T12:02:57+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-verstaerkt-fuehrungsteam-mit-ernennung-des-erfahrenen-branchenexperten-axel-sven-malkomes-zum-chief-financial-officer/ 2024-11-04T12:06:16+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-strengthens-leadership-team-with-appointment-of-seasoned-industry-executive-axel-sven-malkomes-as-chief-financial-officer/ 2024-11-04T12:06:16+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-am-12-november-2024-finanzergebnisse-des-dritten-quartals-sowie-der-ersten-neun-monate-2024-und-informiert-ueber-seine-geschaeftsentwicklung/ 2024-11-07T12:04:20+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-zweite-quartal-und-das-erste-halbjahr-2024-und-informiert-ueber-seine-geschaeftsentwicklung/ 2024-11-09T21:40:00+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/wp-content/uploads/2024/03/Patrick_Miescher-1-150x150.png https://www.curevac.com/en/curevac-to-report-third-quarter-and-first-nine-months-2024-financial-results-and-business-update-on-november-12-2024/ 2024-11-13T18:01:47+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-third-quarter-and-first-nine-months-of-2024-and-provides-business-update/ 2024-11-13T18:05:41+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-39th-annual-meeting/ 2024-11-13T18:06:21+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-praesentiert-auf-der-12-international-mrna-health-conference/ 2024-11-13T18:07:38+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-dritte-quartal-und-die-ersten-neun-monate-2024-und-informiert-ueber-seine-geschaeftsentwicklung/ 2024-11-13T18:13:46+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-praesentiert-auf-der-39-jahrestagung-der-society-for-immunotherapy-of-cancer-sitc/ 2024-11-13T18:13:58+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-erneut-von-lexisnexis-als-eines-der-weltweit-fuehrenden-innovationsunternehmen-ausgezeichnet/ 2025-02-18T12:06:07+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-earns-repeat-recognition-by-lexisnexis-as-one-of-the-worlds-top-innovators/ 2025-02-18T12:06:14+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-receives-positive-validity-decision-from-european-patent-office-in-litigation-against-biontech-se/ 2025-04-02T13:04:27+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-erhaelt-positive-entscheidung-zur-patentgueltigkeit-vom-europaeischen-patentamt-im-rechtsstreit-mit-biontech-se/ 2025-04-03T07:17:56+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-to-report-fourth-quarter-and-full-year-2024-financial-results-and-business-update-on-april-10-2025/ 2025-04-08T11:05:03+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-am-10-april-2024-finanzergebnisse-des-vierten-quartals-sowie-des-gesamtjahres-2024-und-informiert-ueber-seine-geschaeftsentwicklung/ 2025-04-08T11:05:03+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-vierte-quartal-sowie-das-gesamtjahr-2024-und-informiert-ueber-seine-geschaeftsentwicklung/ 2025-04-10T11:29:08+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-announces-financial-results-for-the-fourth-quarter-and-full-year-2024-and-provides-business-update/ 2025-04-10T11:29:08+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-receives-u-s-fda-ind-clearance-to-initiate-phase-1-clinical-trial-for-novel-mrna-based-precision-immunotherapy-in-squamous-non-small-cell-lung-cancer/ 2025-04-15T13:51:50+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/curevac-erhaelt-ind-freigabe-der-u-s-amerikanischen-fda-fuer-den-start-einer-klinischen-phase-1-studie-mit-einer-neuartigen-mrna-praezisions-immuntherapie-beim-plattenepithelkarzinom-der-lunge/ 2025-04-15T13:52:55+00:00 https://www.curevac.com/wp-content/uploads/2022/07/Sarah5133b_highres-mit-Farbe-150x150.jpg https://www.curevac.com/en/curevac-receives-additional-positive-validity-decision-from-european-patent-office-in-ongoing-litigation-against-biontech-se/ 2025-05-15T20:12:37+00:00 https://www.curevac.com/curevac-erhaelt-weitere-positive-entscheidung-zur-patentgueltigkeit-vom-europaeischen-patentamt-im-laufenden-rechtsstreit-mit-biontech-se/ 2025-05-15T20:12:37+00:00 https://www.curevac.com/en/curevac-announces-financial-results-for-the-first-quarter-of-2025-and-provides-business-updates/ 2025-05-20T11:03:46+00:00 https://www.curevac.com/curevac-veroeffentlicht-finanzergebnisse-fuer-das-erste-quartal-2025-und-informiert-ueber-seine-geschaeftsentwicklung/ 2025-05-20T11:06:09+00:00 https://www.curevac.com/en/biontech-announces-strategic-transaction-to-acquire-curevac-in-public-exchange-offer/ 2025-06-12T11:07:29+00:00 https://www.curevac.com/biontech-kuendigt-strategische-transaktion-zur-uebernahme-von-curevac-im-rahmen-eines-oeffentlichen-umtauschangebots-an/ 2025-06-12T11:58:13+00:00